Andrew Powaleny Andrew Powaleny is Director of Public Affairs at PhRMA. Before joining PhRMA in 2015, he worked at the House Energy and Commerce Committee and later as a communications consultant. Andrew came to Washington, D.C. via Connecticut and proudly sings with the Gay Men’s Chorus of Washington, runs with the DC Front Runners and serves on the Alumni Council for The Fund for American Studies. He is also a member of the National Lesbian Gay Journalists Association.
Recent Posts
New report shows nearly 300 cell and gene therapies in development
By Andrew Powaleny | December 6, 2018
Fifty years ago, the idea of altering a gene to treat or even cure a disease was considered science fiction. Today, cell and gene therapy are transforming treatment options for some patients and...
Read More
World AIDS Day 2018: Hope for the future
By Andrew Powaleny | December 1, 2018
Each year, I write to commemorate World AIDS Day which is now in its 30th year spotlighting patients living with HIV and those we’ve sadly lost to AIDS-related illnesses.
Read More
New report shows more than 300 skin disease medicines in development
By Andrew Powaleny | September 25, 2018
More than 100 million Americans – one third of the U.S. population – suffer from skin conditions.
Read More
Disrupting Alzheimer's
By Andrew Powaleny | September 10, 2018
We are living in a new era of medicine, where treatments and even cures once believed to be impossible are today a reality. But this immense progress does not apply universally and there have been...
Read More
Here’s how America’s biopharmaceutical companies lead the way in development of innovative new medicines
By Andrew Powaleny | July 25, 2018
In today’s new era of medicine, America’s biopharmaceutical companies are conducting some of the most complex and difficult research in the world to develop innovative treatments for patients.
Read More
Event next week: Supporting the next generation of lifesaving medicines
By Andrew Powaleny | July 12, 2018
The remarkable scientific advancements in recent history are due, in part, to thoughtful public policies that promote innovation and discovery. These policies support the tireless efforts of more...
Read More
Nearly 60 biopharmaceutical researchers GoBoldly on Capitol Hill
By Andrew Powaleny | June 14, 2018
This week, the new era of medicine was brought to Capitol Hill in Washington, DC when 55 biopharmaceutical researchers from 20 PhRMA member companies held 79 meetings with members of Congress and...
Read More
Diversity of thought fuels next generation of breakthroughs
By Andrew Powaleny | June 7, 2018
This month, PhRMA is proud to join with our member companies to celebrate Lesbian, Gay, Bisexual and Transgender (LGBT) PRIDE Month.
Read More
New report and resources put cancer in context, showing more than 1,100 medicines and vaccines in development
By Andrew Powaleny | May 30, 2018
In the not too distant past, chemotherapy and radiation were once the only treatments for what remains the second leading cause of death in the United States – cancer. Although the death rates of...
Read More
Despite the current unprecedented pace of biopharmaceutical innovation, patients continue to face rising out-of-pocket costs and other barriers to care. Tomorrow, in partnership with The Atlantic,...
Read More
Medicare Monday (100)
340B Spotlight (37)
Cost & Consequence (0)
